Insider Selling: Atara Biotherapeutics Inc (ATRA) CEO Sells 7,800 Shares of Stock

Atara Biotherapeutics Inc (NASDAQ:ATRA) CEO Isaac E. Ciechanover sold 7,800 shares of the firm’s stock in a transaction on Tuesday, May 14th. The shares were sold at an average price of $24.61, for a total value of $191,958.00. Following the completion of the transaction, the chief executive officer now owns 332,243 shares in the company, valued at approximately $8,176,500.23. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Shares of NASDAQ:ATRA traded down $0.73 during midday trading on Thursday, reaching $24.12. 21,716 shares of the company’s stock were exchanged, compared to its average volume of 550,702. The company has a current ratio of 9.96, a quick ratio of 9.96 and a debt-to-equity ratio of 0.05. The company has a market capitalization of $1.12 billion, a price-to-earnings ratio of -4.58 and a beta of 2.11. Atara Biotherapeutics Inc has a fifty-two week low of $23.58 and a fifty-two week high of $54.45.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($1.44) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.48) by $0.04. As a group, equities research analysts predict that Atara Biotherapeutics Inc will post -5.93 earnings per share for the current fiscal year.

A number of research analysts have weighed in on ATRA shares. Mizuho started coverage on Atara Biotherapeutics in a report on Tuesday, January 22nd. They issued a “buy” rating and a $62.00 price objective on the stock. BidaskClub upgraded Atara Biotherapeutics from a “hold” rating to a “buy” rating in a report on Thursday, February 7th. ValuEngine lowered Atara Biotherapeutics from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 12th. Cowen reiterated a “buy” rating on shares of Atara Biotherapeutics in a report on Tuesday, February 26th. Finally, Zacks Investment Research lowered Atara Biotherapeutics from a “hold” rating to a “sell” rating in a report on Monday, March 4th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $43.33.

Several large investors have recently modified their holdings of the stock. FMR LLC increased its position in shares of Atara Biotherapeutics by 21.7% during the 1st quarter. FMR LLC now owns 6,417,956 shares of the biotechnology company’s stock worth $255,114,000 after purchasing an additional 1,143,787 shares during the last quarter. Maverick Capital Ltd. acquired a new position in Atara Biotherapeutics in the 1st quarter valued at about $34,613,000. Man Group plc acquired a new position in Atara Biotherapeutics in the 1st quarter valued at about $1,128,000. Coastal Investment Advisors Inc. acquired a new position in Atara Biotherapeutics in the 1st quarter valued at about $142,000. Finally, Marshall Wace LLP acquired a new position in Atara Biotherapeutics in the 1st quarter valued at about $284,000.

COPYRIGHT VIOLATION NOTICE: “Insider Selling: Atara Biotherapeutics Inc (ATRA) CEO Sells 7,800 Shares of Stock” was posted by Modern Readers and is the sole property of of Modern Readers. If you are accessing this report on another site, it was illegally stolen and reposted in violation of international trademark & copyright law. The legal version of this report can be read at https://www.modernreaders.com/news/2019/05/16/insider-selling-atara-biotherapeutics-inc-atra-ceo-sells-7800-shares-of-stock.html.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.

Recommended Story: Trade Deficit

Insider Buying and Selling by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.